文献速递脊柱关节炎

乌帕替尼治疗活动性强直性脊柱炎一年安全性及有效性

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
PubMed 文献 · Arthritis Rheumatol · 2021-11-12

SELECT-AXIS 1研究纳入187例活动性强直性脊柱炎且对非甾体抗炎药应答不足的患者,随机接受乌帕替尼15 mg每日一次或安慰剂,第14周安慰剂组转为乌帕替尼,开放扩展至第104周,本次报告第64周数据。结果显示乌帕替尼持续有效,两组疗效相似,未报告严重感染、主要心血管不良事件、静脉血栓栓塞、胃肠道穿孔或死亡。

要点

  • 乌帕替尼15 mg每日一次治疗活动性强直性脊柱炎疗效持续至1年。
  • 第14周由安慰剂转为乌帕替尼者与持续用药者疗效相似。
  • 未报告严重感染、主要心血管不良事件、静脉血栓栓塞、胃肠道穿孔或死亡。

核心结论

  • 乌帕替尼15 mg每日一次在活动性强直性脊柱炎患者中显示持续且一致的有效性至1年。
  • 第14周从安慰剂转换为乌帕替尼的患者与持续接受乌帕替尼的患者疗效相似。

研究设计与样本

  • SELECT-AXIS 1研究为双盲、安慰剂对照试验及开放标签扩展,纳入187例活动性强直性脊柱炎且对非甾体抗炎药应答不足的成人患者。
  • 患者随机接受乌帕替尼15 mg每日一次或安慰剂,第14周安慰剂组转为乌帕替尼,所有患者继续开放扩展至第104周,本次报告第64周中期数据。

主要发现

  • 187例患者中178例完成第14周研究药物并进入开放扩展。
  • 第64周时,持续乌帕替尼组与安慰剂转乌帕替尼组达到ASAS40或ASDAS低疾病活动度的比例相似:基于NRI分析≥70%患者达到这些终点,基于as-observed分析≥81%。
  • 第64周时,基于NRI分析≥34%、基于as-observed分析≥39%的患者达到ASDAS不活动疾病或ASAS部分缓解。
  • 从基线(第0周)至第64周,疼痛、功能和炎症的平均变化显示持续改善或维持。
  • 182例接受乌帕替尼治疗的患者(237.6患者年)中报告618例不良事件(260.1例/100患者年);未报告严重感染、主要心血管不良事件、静脉血栓栓塞事件、胃肠道穿孔或死亡。

关键数值与推荐

  • 第64周达到ASAS40或ASDAS低疾病活动度:NRI分析≥70%,as-observed分析≥81%。
  • 第64周达到ASDAS不活动疾病或ASAS部分缓解:NRI分析≥34%,as-observed分析≥39%。
  • 182例接受乌帕替尼治疗的患者(237.6患者年)中报告618例不良事件(260.1例/100患者年)。

临床怎么用

  • 对于活动性强直性脊柱炎且对非甾体抗炎药应答不足的成人患者,乌帕替尼15 mg每日一次可考虑作为治疗选择,疗效可持续至1年。
  • 治疗期间需关注不良事件,但本研究报告未出现严重感染、主要心血管不良事件、静脉血栓栓塞、胃肠道穿孔或死亡。

局限性

  • 本次报告为第64周中期数据,开放标签扩展至第104周的数据尚未完整报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). METHODS: In the SELECT-AXIS 1 study, adults with active AS and an inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive upadacitinib 15 mg once daily or placebo. At week 14, patients who had been randomized to receive placebo were switched to upadacitinib, and all patients continued in the open-label extension and received upadacitinib up to week 104; interim data up to week 64 are reported herein. RESULTS: Of 187 patients, 178 completed week 14 on study drug and entered the open-label extension. Similar proportions of patients in either group (continuous upadacitinib or placebo-to-upadacitinib) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40) or Ankylosing Spondylitis Disease Activity Score (ASDAS) showing low disease activity at week 64: ≥70% of patients achieved these end points based on nonresponder imputation (NRI) and ≥81% based on as-observed analyses. Furthermore, ≥34% (NRI) and ≥39% (as-observed analysis) achieved ASDAS showing inactive disease or ASAS showing partial remission at week 64. Mean changes from baseline (week 0) to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib (237.6 patient-years), 618 adverse events (260.1 per 100 patient-years) were reported. No serious infections, major adverse cardiovascular events, venous thromboembolic events, gastrointestinal perforation, or deaths were reported. CONCLUSION: Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Deodhar A, van der Heijde D, Sieper J, et al. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. 2021. PMID: 34196498. doi:10.1002/art.41911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。